Mitomycin C (MMC)
Sponsors
Shahid Beheshti University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Shaogang Wang, First Affiliated Hospital of Wenzhou Medical University
Conditions
Bladder CancerCarcinoma in Situ of BladderCarcinoma, Transitional CellNon-Muscle-Invasive Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)Peritoneal CarcinomatosisRefractory GlaucomaUrinary Bladder Neoplasms
Phase 1
Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma
NCT00893490
Updated: 2009-05-06
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
Not yet recruitingNCT07487168
Start: 2026-08-01End: 2028-03-01Target: 24Updated: 2026-05-15
Phase 2
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Not yet recruitingNCT07189793
Start: 2025-10-31End: 2028-10-31Target: 106Updated: 2025-09-24
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
RecruitingNCT07646145
Start: 2024-04-01End: 2027-04-01Target: 30Updated: 2026-06-12
Phase 3
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
TerminatedNCT00974818
Start: 2009-09-30End: 2012-03-31Updated: 2015-11-20
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Active, not recruitingNCT04241185
Start: 2020-05-19End: 2031-11-01Target: 520Updated: 2026-05-01
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
RecruitingNCT06696794
Start: 2025-02-17End: 2031-06-30Target: 180Updated: 2025-02-19